Please ensure Javascript is enabled for purposes of website accessibility

Why Marijuana Stocks Canopy Growth, Cronos Group, and Tilray Plunged in August but Rebounded in Early September

By Joe Tenebruso – Sep 14, 2019 at 10:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investor sentiment toward the cannabis industry can shift quickly.

What happened

Shares of Canopy Growth (CGC 0.36%), Cronos Group (CRON -2.39%), and Tilray (TLRY) plummeted 28%, 20%, and 37% last month, respectively, according to data provided by S&P Global Market Intelligence. However, these popular cannabis stocks have gained back much of their losses so far in September.

So what

A host of factors have weighed on the cannabis industry in recent months. Regulatory delays in Canada, high tax rates in major U.S. markets such as California, compliance scandals, and cheaper illegally produced marijuana are just some of the challenges cannabis companies have had to contend with.

These obstacles have dented the operating results of the major marijuana producers -- so much so that Canopy Growth, Cronos Group, and Tilray will all likely lose money not just in 2019 but also in 2020.

Many investors appear to be losing patience with marijuana companies, and short-term-minded hedge funds have been bailing on cannabis stocks in recent quarters.

A volatile stock chart superimposed over cannabis plants.

Tilray, Canopy Growth, and Cronos Group have seen their stocks rebound sharply so far in September. Image source: Getty Images.

Now what

Yet thus far in September, many investors are becoming more bullish in their view of marijuana stocks.

Investment bank Seaport Global upgraded Canopy Growth's stock to buy from neutral and boosted its target price to $31 per share. Seaport Global analyst Brett Hundley cited Canopy's cash-rich balance sheet and valuable collection of cannabis-related intellectual property as reasons for his bullish outlook.

Cronos Group received praise from analysts at Bank of America for its acquisition of several of Redwood Holding Group's subsidiaries, which will give it control of the Lord Jones brand of cannabidiol (CBD) beauty products. BofA analyst Christopher Carey said it could be the first of many acquisitions for Cronos in the fast-growing CBD space.

Tilray, meanwhile, saw its shares rise even when a Wall Street analyst cut her target price for its stock. Cowen analyst Vivien Azer slashed her price target from $150 to $60, due in part to supply constraints in Canada that are stifling Tilray's growth. Yet Azer believes Tilray could still outperform other cannabis stocks from this point forward due to its efforts to boost production, new retail store openings in Canada, and the company's intriguing opportunities in international markets. That's why, even at its significantly reduced level, Azer's new $60 price target still represents approximately 100% upside from Tilray's current price.

All told, Cronos Group, Canopy Growth, and Tilray have seen their stocks rise 5%, 16%, and 20%, respectively, so far this month. And if they can prove to investors that they can capture a larger share of a cannabis industry that could one day generate $200 billion in annual sales, more gains may still lie ahead.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
CGC
$2.79 (0.36%) $0.01
Cronos Group Stock Quote
Cronos Group
CRON
$2.86 (-2.39%) $0.07
Tilray Stock Quote
Tilray
TLRY

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.